{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:18:53Z","timestamp":1773829133887,"version":"3.50.1"},"reference-count":19,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The COVID-19 pandemic is changing rapidly and requires different strategies to maintain immunization. In Korea, different COVID-19 vaccines are recommended and available for various populations, including healthcare workers (HCWs) at high risk of SARS-CoV-2 infection. We plan to evaluate the adverse events (AEs) and immunogenicity of the BNT162b2 and ChAdOx1 vaccines in HCWs at a single center. This cohort study included HCWs fully vaccinated with either BNT162b2 or ChAdOx1. Blood samples were taken eight weeks after the second vaccination with both COVID-19 vaccines and six months after the second vaccination from participants with the BNT162b2 vaccine. The primary endpoint for immunogenicity was the serum neutralizing antibody responses eight weeks after vaccination. The secondary endpoint was the incidence of various AEs within 28 days of each vaccination. Between 16 March and 23 June 2021, 115 participants were enrolled (65 in the ChAdOx1 group and 50 in the BNT162b2 group). Significantly higher surrogate virus neutralization test (sVNT) inhibition was observed in participants vaccinated with two doses of BNT162b2 (mean (SD) 91.4 (9.68)%) than in those vaccinated with ChAdOx1 (mean (SD) 73.3 (22.57)%). The effectiveness of the BNT162b2 vaccine was maintained across all age and gender categories. At six months after the second dose, serum antibody levels declined significantly in the BNT162b2 group. The main adverse events, including fever, myalgia, fatigue, and headache, were significantly higher in the ChAdOx1 group after the first dose, whereas, after the second dose, those AEs were significantly higher in the BNT162b2 group (p &lt; 0.05). Two doses of either the ChAdOx1 or the BNT162b2 COVID-19 vaccine resulted in very high seropositivity among the HCWs at our center. The quality of the antibody response, measured by sVNT inhibition, was significantly better with the BNT162b2 vaccine than with the ChAdOx1 vaccine. There was no significant association between neutralizing antibody response and AE after each vaccination in our cohort.<\/jats:p>","DOI":"10.3390\/vaccines9121379","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T03:12:56Z","timestamp":1638328376000},"page":"1379","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-9994","authenticated-orcid":false,"given":"Sung-Hee","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Hyeok","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bora","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Youn","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Sok","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-9950","authenticated-orcid":false,"given":"Chan-Kyu","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tark","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2842-7041","authenticated-orcid":false,"given":"Eun-Ju","family":"Choo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Disease, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-7463","authenticated-orcid":false,"given":"Ji-Eun","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-8309","authenticated-orcid":false,"given":"Jina","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Kyu","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"ref_2","unstructured":"WHO (2021, July 01). Coronavirus Disease (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int."},{"key":"ref_3","unstructured":"CDC (Central Disease Control) (2021, July 15). Coronavirus (COVID-19) Dashboard, Republic of Korea. Available online: http:\/\/ncov.mohw.go.kr\/en\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e02438-20","DOI":"10.1128\/JCM.02438-20","article-title":"A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection","volume":"59","author":"Taylor","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_9","unstructured":"Hinton, R.D.M. (2021, November 20). Table of Tests Acceptable for Use in the Manufacture of High Titer COVID-19. Convalescent Plasma, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/anti-sars-cov-2-antibody-products\/convalescent-plasma\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103101","DOI":"10.1016\/j.ebiom.2020.103101","article-title":"Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity","volume":"62","author":"Padoan","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e02107-20","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate","volume":"58","author":"Addetia","year":"2020","journal-title":"Clin. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41423-020-00573-9","article-title":"Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods","volume":"18","author":"Stein","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Park, J.Y., and Choi, S.H. (2021). Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132844"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kim, T., Park, S.Y., Yu, S., Park, J.W., Lee, E., Jeon, M.H., Kim, T.H., and Choo, E.J. (2021). Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea. Vaccines, 9.","DOI":"10.3390\/vaccines9060648"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"Cox","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study","volume":"2","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1379\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:59Z","timestamp":1760168099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["vaccines9121379"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9121379","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}